British biotech rebrands as Octavian, seeking to establish new empire after setbacks in 2024
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as Octavian Therapeutics to align with its “growth ambitions and its transition to a privately held company.”
Oxford Cannabinoid Technologies is shedding its old skin. Having delisted its stock last year, the biotech is rebranding as Octavian Therapeutics to align with its “growth ambitions and its transition to a privately held company.”
